Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7567185 | 0.94 | HPRT1 (0.47) | HPRT1CYP1A2CYP3A4KMT2AMEN1 | |
| SCHEMBL7571914 | 0.85 | HPRT1 (0.49) | HPRT1CYP1A2CYP3A4KMT2AMEN1 | |
| SCHEMBL7576799 | 0.85 | HPRT1 (0.51) | HPRT1KMT2AMEN1LMNA | |
| SCHEMBL7570980 | 0.84 | HPRT1 (0.48) | HPRT1CYP1A2CYP3A4KMT2AMEN1 | |
| SCHEMBL7570913 | 0.83 | HPRT1 (0.50) | HPRT1 | |
| SCHEMBL7570961 | 0.83 | HPRT1 (0.46) | HPRT1KMT2AMEN1ALDH1A1HSD17B10 | |
| SCHEMBL7570074 | 0.83 | HPRT1 (0.53) | HPRT1KMT2AGAAALDH1A1KDM4E | |
| SCHEMBL7575108 | 0.83 | HPRT1 (0.53) | HPRT1 | |
| SCHEMBL7982326 | 0.81 | HPRT1 (0.51) | HPRT1GAAALDH1A1KDM4E | |
| SCHEMBL7980707 | 0.80 | TSHR (0.45) | HPRT1KMT2AMEN1NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237890-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | Neotherapeutics, Inc. (US) | 2002-09-11 | — | — | EP | claimed |
| US-6297226-B1 | TREATING A DISEASE OR A CONDITION IN A MAMMAL TREATABLE BY INHIBITING THE ACTIVITY OF A MONOAMINE OXIDASE | NEOTHERAPEUTICS, INC. | 2001-10-02 | — | — | US | claimed |
| WO-2001029039-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | claimed |
| EP-1237890-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | Neotherapeutics, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-6297226-B1 | TREATING A DISEASE OR A CONDITION IN A MAMMAL TREATABLE BY INHIBITING THE ACTIVITY OF A MONOAMINE OXIDASE | NEOTHERAPEUTICS, INC. | 2001-10-02 | — | — | US | disclosed |
| WO-2001029039-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |